1[1]Ariyama J,Suyama M,Satoh K,et al.Imaging of small pancreatic ductal adenocarcinoma.Pancreas, 1998,16(3):396-401
2[2]Cerwenka H,Aigner R,Quehenbeger F,et al.Preoperative differential diagnosis of benign and malignant pancreatic lesions-the value of pancreatic secretory trypsin inhibitor,procarboxypeptidase B,CA19-9 and CEA. Hepatogastroenterology, 1997,44(66):1117-21
3[3]Safi F,Schlosser W, Falkenreck S, et al. Prognostic value of CA19-9 serum course in pancreatic cancer. Hepatogastroenterology, 1998,45(19):253-9
4[4]Montgomery RC, Hoffman JP, Riley LB, et al.Preolition of recurrence and survival by postresection CA19-9 values in patients with adenocarcionma of the pancreas.Ann Surg Oncol, 1997,4(7):551-6
5[5]Gogas H, Lofts FJ, Evans TR,et al.Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarainoma of the pancreas?Br J Cancer, 1998,77(2):325-8
6[6]Yiannakou JY,Newland P,Calder F, et al.Prospective study of CAM17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet, 1997,349:389(9049)-92
7[7]Reubi JC, Waser B, Friess H,et al. Neurotensin receptors:a new marker for human ductal pancreatic adenocarcinoma. Gut, 1998,42(4):546-50
8[8]Ichikawa T, Haradome H,Hachiya J,et al.pancreatic ductal adenocarcinoma:preoperative assessment with helical CT versus dynamic MR imaging. Radiology, 1997,202(3):655-62
9[9]Irie H,Honda H,Kaneko K,et al.Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma. Abdom Imaging, 1997,22(4):429-33
10[10]Reptopoulos V,Steer ML,Sheiman RG,et al.The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer:correlation with findings at surgery.AJR Am J Roentgenol, 1997,168(4):971-7
